Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 13;9(89):35997–36011. doi: 10.18632/oncotarget.26323

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2018 Ueda et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

(A) Left panel shows IgG responses measured by ELISA assay to MAGE-A4 protein in patients who had pre-existing IgG to NY-ESO-1 antigen (n = 11). Right panel shows IgG responses to NY-ESO-1 protein in the same patients. (B) Left panel shows IgG responses measured by ELISA assay to MAGE-A4 protein in patients who did not have pre-existing IgG to NY-ESO-1 antigen (n = 10). Right panel shows IgG responses to NY-ESO-1 protein in the same patients. (C) Left panel shows IgG responses to MAGE-A4 protein in patients whose tumors did not express NY-ESO-1 antigen (n = 13). Right panel shows IgG responses to NY-ESO-1 protein in the same patients. (D) Left panel shows IgG responses to MAGE-A4 protein in patients whose tumors expressed NY-ESO-1 antigen (n = 6). Right panel shows IgG responses to NY-ESO-1 protein in the same patients.

(A) Left panel shows IgG responses measured by ELISA assay to MAGE-A4 protein in patients who had pre-existing IgG to NY-ESO-1 antigen (n = 11). Right panel shows IgG responses to NY-ESO-1 protein in the same patients. (B) Left panel shows IgG responses measured by ELISA assay to MAGE-A4 protein in patients who did not have pre-existing IgG to NY-ESO-1 antigen (n = 10). Right panel shows IgG responses to NY-ESO-1 protein in the same patients. (C) Left panel shows IgG responses to MAGE-A4 protein in patients whose tumors did not express NY-ESO-1 antigen (n = 13). Right panel shows IgG responses to NY-ESO-1 protein in the same patients. (D) Left panel shows IgG responses to MAGE-A4 protein in patients whose tumors expressed NY-ESO-1 antigen (n = 6). Right panel shows IgG responses to NY-ESO-1 protein in the same patients.